Enfuvirtide (T-20, Fuzeon)
- Enfuvirtide is an injectable anti-HIV drug approved by the FDA for people with multi-drug resistance to other anti-HIV therapies.
- It appears safe, with the primary side effect of injection site reactions.
- Enfuvirtide appears to be active and useful for people who have failed other therapies and represents a hopeful new option for people.
- Being an injectable therapy, it may be difficult to use and requires training for doctors and patients alike to administer the drug to maximize benefits and minimize side effects.
- The new protease inhibitor is designed for once daily dosing; its ease of use provides an intriguing option for part of a first line regimen. When boosted with a small amount of ritonavir it may provide an additional tool in the arsenal for third line therapy.
- There are many potential drug interactions with atazanavir, and people are encouraged to pay particular attention to these when adding this drug to their regimen.
Emtricitabine (FTC, Emtriva)
- This NRTI appears similar to 3TC (lamivudine, Epivir), but requires only once-daily dosing and resistance may be less likely to develop to FTC.
- More studies are needed to identify the true value and role of FTC.
Back to the Project Inform Perspective October 2003 contents page.